Naratriptan
- Generic Name
- Naratriptan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2S
- CAS Number
- 121679-13-8
- Unique Ingredient Identifier
- QX3KXL1ZA2
- Background
Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
- Indication
For the acute treatment of migraine attacks with or without aura in adults.
- Associated Conditions
- Migraine with acute onset aura, Acute Migraine without aura
- Associated Therapies
- -
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Ache Laboratorios Farmaceuticos S.A.
- Registration Number
- NCT01726920
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Ache Laboratorios Farmaceuticos S.A.
- Registration Number
- NCT01390324
Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 500
- Registration Number
- NCT01376193
Special Drug Use Investigation for AMERGE® Tablet (Long-term)
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT01332383
Sumatriptan and Naratriptan Pregnancy Registry
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 868
- Registration Number
- NCT01059604
Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 8
- Registration Number
- NCT00282165
- Locations
- 🇳🇱
FPC De Kijvelanden, Poortugaal, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath